Maternal Near Miss in Patients with Systemic Lupus Erythematosus
Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics · 01.01.2023 · 45 (01) · 011-020
DOI: 10.1055/s-0042-1759633 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics, erschienen am 01.01.2023. Verfasst von Arlley Cleverson Belo da Silva und 5 weiteren Autor:innen. Beteiligte Einrichtung: Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil. Hauptthemen laut MEDLINE: Near Miss, Healthcare, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Systemic lupus erythematosus (SLE) may cause irreversible organ damage. Pregnancy with SLE may have severe life-threatening risks. The present study aimed to determine the prevalence of severe maternal morbidity (SMM) in patients with SLE and analyze the parameters that contributed to cases of greater severity.
Methods
This is a cross-sectional retrospective study from analysis of data retrieved from medical records of pregnant women with SLE treated at a University Hospital in Brazil. The pregnant women were divided in a control group without complications, a group with potentially life-threatening conditions (PLTC), and a group with maternal near miss (MNM).
Results
The maternal near miss rate was 112.9 per 1,000 live births. The majority of PLTC (83.9%) and MNM (92.9%) cases had preterm deliveries with statistically significant increased risk compared with the control group (p = 0.0042; odds ratio [OR]: 12.05; 95% confidence interval [CI]: 1.5–96.6 for the MNM group and p = 0.0001; OR: 4.84; 95%CI: 2.2–10.8 for the PLTC group). Severe maternal morbidity increases the risk of longer hospitalization (p < 0.0001; OR: 18.8; 95%CI: 7.0–50.6 and p < 0.0001; OR: 158.17; 95%CI: 17.6–1424,2 for the PLTC and MNM groups, respectively), newborns with low birthweight (p = 0.0006; OR: 3.67; 95%CI: 1.7–7.9 and p = 0.0009; OR: 17.68; 95%CI: 2–153.6) for the PLTC and MNM groups, respectively] as well as renal diseases (PLTC [8.9%; 33/56; p = 0.0069] and MNM [78.6%; 11/14; p = 0.0026]). Maternal near miss cases presented increased risk for neonatal death (p = 0.0128; OR: 38.4; 95%CI: 3.3–440.3]), and stillbirth and miscarriage (p = 0.0011; OR: 7.68; 95%CI: 2.2–26.3]).
Conclusion
Systemic lupus erythematosus was significantly associated with severe maternal morbidity, longer hospitalizations, and increased risk of poor obstetric and neonatal outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
- Universidade Estadual de Campinas, Campinas, SP, Brazil.
ORCID-Profile: Arlley Cleverson Belo da Silva, Sue Yazaki Sun, Felipe Favorette Campanharo, Letícia Tiemi Morooka, José Guilherme Cecatti, Rosiane Mattar
Zitieren
APA
Silva, A. C. B. D., Sun, S. Y., Campanharo, F. F., Morooka, L. T., Cecatti, J. G., & Mattar, R. (2023). Maternal Near Miss in Patients with Systemic Lupus Erythematosus. Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics, 45(01), 011-020. https://doi.org/10.1055/s-0042-1759633
Vancouver
Silva ACBD, Sun SY, Campanharo FF, Morooka LT, Cecatti JG, Mattar R. Maternal Near Miss in Patients with Systemic Lupus Erythematosus. Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics. 2023;45(01):011-020. doi:10.1055/s-0042-1759633
BibTeX
@article{Silva2023,
author = {Silva, Arlley Cleverson Belo da and Sun, Sue Yazaki and Campanharo, Felipe Favorette and Morooka, Letícia Tiemi and Cecatti, José Guilherme and Mattar, Rosiane},
title = {Maternal Near Miss in Patients with Systemic Lupus Erythematosus},
journal = {Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics},
year = {2023},
volume = {45},
number = {01},
pages = {011--020},
doi = {10.1055/s-0042-1759633}
}
EUVIMED